Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A double-'blind', placebo-controlled trial of topical therapy with 15% paromomycin (aminosidine) and 10% urea in white paraffin was carried out on 53 patients with non-ulcerating cutaneous leishmaniasis in Honduras. Although the treatment was not effective, several unexpected findings emerged from the trial. Leishmania mexicana was found to be the cause of many of the skin lesions in one of the 2 study sites. These lesions were clinically indistinguishable from those caused by L. chagasi, the aetiologic agent previously found for this form of leishmaniasis. This is the first documented report of L. mexicana in Honduras.

Original publication




Journal article


Transactions of the Royal Society of Tropical Medicine and Hygiene

Publication Date





473 - 475


Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland, USA.


Skin, Animals, Humans, Leishmania mexicana, Leishmaniasis, Cutaneous, Paromomycin, Antiprotozoal Agents, Administration, Topical, Double-Blind Method, Adolescent, Adult, Child, Child, Preschool, Honduras, Female, Male